The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Background The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who were...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer Ročník 124; číslo 21; s. 4241 - 4247
Hlavní autoři:	DuBois, Steven G., Laetsch, Theodore W., Federman, Noah, Turpin, Brian K., Albert, Catherine M., Nagasubramanian, Ramamoorthy, Anderson, Megan E., Davis, Jessica L., Qamoos, Hope E., Reynolds, Mark E., Cruickshank, Scott, Cox, Michael C., Hawkins, Douglas S., Mascarenhas, Leo, Pappo, Alberto S.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Wiley Subscription Services, Inc 01.11.2018 John Wiley and Sons Inc
Témata:	Children Complications Enzyme inhibitors Evaluation Fibrosarcoma infantile fibrosarcoma Inhibitors larotrectinib local control Morbidity neurotrophic receptor tyrosine kinase (NTRK) Oncology Original Patients pediatric Pediatrics Sarcoma Solid tumors Surgery Therapy Tropomyosin tropomyosin receptor kinase (TRK) fusion Tumors Wound healing larotrectinib sarcoma tropomyosin receptor kinase (TRK) fusion local control neurotrophic receptor tyrosine kinase (NTRK) infantile fibrosarcoma pediatric surgery
ISSN:	0008-543X, 1097-0142, 1097-0142
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!